Cabaletta Bio Inc
CABA2.395USD
-0.085-3.43%
交易中 （美東）報價延遲15分鐘
219.03M總市值
虧損本益比TTM
關於 Cabaletta Bio Inc 公司
Cabaletta Bio, Inc. 是一家臨牀階段的生物技術公司。該公司專注於發現和開發工程化 T 細胞療法，這些療法有可能通過一次性給藥爲自身免疫性疾病患者提供深度和持久的、甚至治癒性的反應。其 Cabaletta B 細胞消融方法 (CABA) 平臺包含兩種策略：自身免疫嵌合抗原受體 T 細胞 (CARTA) 和嵌合自身抗體受體 T 細胞 (CAART)。CABA-201 是其 CARTA 平臺的主要候選產品，是一種含有 4-1BB 共刺激結構域的全人 CD19-CAR T 構建體，旨在治療患有一系列自身免疫性疾病的患者。其 DSG3-CAART 候選產品正在第 1 階段 DesCAARTes TM 試驗中接受評估，用於治療 mPV，一種影響粘膜上皮的 PV 亞型。其 MuSK-CAART 候選產品旨在治療一組 MG 患者，針對自身反應性 B 細胞。
Cabaletta Bio Inc簡介
公司代碼CABA
公司名稱Cabaletta Bio Inc
上市日期Oct 25, 2019
CEODr. Steven Nichtberger, M.D.
員工數量161
證券類型Ordinary Share
年結日Oct 25
公司地址2929 Arch Street
城市PHILADELPHIA
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編19104
電話12677593100
網址https://www.cabalettabio.com/
公司代碼CABA
上市日期Oct 25, 2019
CEODr. Steven Nichtberger, M.D.
Cabaletta Bio Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Steven Nichtberger, M.D.
Dr. Steven Nichtberger, M.D.
Chief Executive Officer, President, Chairman of the Board, Co-Founder
Chief Executive Officer, President, Chairman of the Board, Co-Founder
1.35M
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Dr. David J. Chang, M.D.
Dr. David J. Chang, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Catherine Bollard, M.D.
Dr. Catherine Bollard, M.D.
Independent Director
Independent Director
--
--
Mr. Mark J. Simon
Mr. Mark J. Simon
Independent Director
Independent Director
--
--
Ms. Shawn Cline Tomasello
Ms. Shawn Cline Tomasello
Independent Director
Independent Director
--
--
Mr. Richard Conover Henriques, Jr.
Mr. Richard Conover Henriques, Jr.
Independent Director
Independent Director
--
--
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
President - Science and Technology
President - Science and Technology
--
--
Dr. Arun Das, M.D.
Dr. Arun Das, M.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Anup Marda
Mr. Anup Marda
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Steven Nichtberger, M.D.
Dr. Steven Nichtberger, M.D.
Chief Executive Officer, President, Chairman of the Board, Co-Founder
Chief Executive Officer, President, Chairman of the Board, Co-Founder
1.35M
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Dr. David J. Chang, M.D.
Dr. David J. Chang, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Catherine Bollard, M.D.
Dr. Catherine Bollard, M.D.
Independent Director
Independent Director
--
--
Mr. Mark J. Simon
Mr. Mark J. Simon
Independent Director
Independent Director
--
--
Ms. Shawn Cline Tomasello
Ms. Shawn Cline Tomasello
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月19日 週二
更新時間: 8月19日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Bain Capital Life Sciences Investors, LLC
10.58%
Adage Capital Management, L.P.
9.65%
Jennison Associates LLC
9.29%
T. Rowe Price Investment Management, Inc.
7.43%
Cormorant Asset Management, LP
5.47%
其他
57.58%
持股股東
持股股東
佔比
Bain Capital Life Sciences Investors, LLC
10.58%
Adage Capital Management, L.P.
9.65%
Jennison Associates LLC
9.29%
T. Rowe Price Investment Management, Inc.
7.43%
Cormorant Asset Management, LP
5.47%
其他
57.58%
股東類型
持股股東
佔比
Investment Advisor
34.03%
Hedge Fund
31.57%
Investment Advisor/Hedge Fund
12.49%
Research Firm
4.00%
Individual Investor
1.65%
Venture Capital
0.11%
Bank and Trust
0.04%
其他
16.10%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
337
75.15M
82.16%
+13.23M
2025Q2
333
45.33M
50.39%
-18.00M
2025Q1
343
38.78M
72.92%
-24.88M
2024Q4
342
40.39M
82.63%
-20.01M
2024Q3
330
50.24M
102.85%
-12.34M
2024Q2
325
53.21M
110.27%
-11.74M
2024Q1
310
53.11M
110.79%
-5.05M
2023Q4
269
50.62M
118.36%
-623.67K
2023Q3
244
42.61M
108.50%
-4.28M
2023Q2
218
38.30M
97.94%
+637.03K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Bain Capital Life Sciences Investors, LLC
9.68M
10.58%
+6.92M
+250.51%
Jun 30, 2025
Adage Capital Management, L.P.
8.83M
9.65%
+5.20M
+142.94%
Jun 30, 2025
Jennison Associates LLC
6.02M
6.58%
+3.59M
+147.36%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
6.79M
7.43%
+2.82M
+71.13%
Jun 30, 2025
Cormorant Asset Management, LP
5.00M
5.47%
+5.00M
--
Jun 30, 2025
Alyeska Investment Group, L.P.
4.80M
5.25%
+4.80M
--
Jun 30, 2025
The Vanguard Group, Inc.
3.45M
3.77%
+606.49K
+21.32%
Jun 30, 2025
Heights Capital Management, Inc.
3.14M
3.44%
+3.14M
--
Jun 30, 2025
T. Rowe Price Associates, Inc.
2.17M
2.38%
+1.72M
+376.17%
Jun 30, 2025
Jefferies LLC
2.00M
2.18%
+2.00M
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
iShares Micro-Cap ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
ProShares UltraPro Russell2000
0%
Optimize Strategy Index ETF
0%
Alger 35 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Value ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
Pacer WealthShield ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.04%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0%
Optimize Strategy Index ETF
佔比0%
Alger 35 ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
Invesco Nasdaq Biotechnology ETF
佔比0%
Invesco Russell 2000 Dynamic Multifactor ETF
佔比0%
Pacer WealthShield ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
